Figure 5

Flow cytometry analysis showing apoptosis and necrosis in HepG2 cancer cells. Treatments were as follows: sorafenib (I), bevacizumab (II), panitumumab (III), ramucirumab (IV), sorafenib-bevacizumab combination (V), sorafenib-panitumumab combination (VI), sorafenib-ramucirumab (VII) combination and untreated (control) HepG2 cancer cells (VIII).